These investigations have demonstrated that the pertuzumab combined with trastuzumab (HP) regimen can further enhance outcomes and prolong survival in patients with HER2-positive breast cancer across neoadjuvant and adjuvant therapy as well as advanced first-line treatment. Here, ERBB2 is linked to breast carcinoma.